Truist Securities Maintains Buy on Disc Medicine, Raises Price Target to $115
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Truist Securities analyst Danielle Brill maintains Disc Medicine (NASDAQ:IRON) with a Buy and raises the price target from $83 to $115.
Truist Securities analyst Danielle Brill maintains Disc Medicine (NASDAQ:IRON) with a Buy and raises the price target from $83 to $115.
